Kindick announced that the company plans to change the initial fund-raising project in 2021, the “construction project to build a new quadrivalent influenza virus lysis vaccine workshop” to a “construction project to build a new novel trivalent influenza virus lysis vaccine workshop”, and the implementation subject and location remain unchanged. This time, the total investment amount involved was 610 million yuan, accounting for 53.71% of the net capital raised. Of these, the remaining capital raised from the original project was invested an additional 10 million yuan into the new project, mainly for the procurement of raw materials and working materials and supplementary working capital. As of September 30, 2026, the original fund-raising project had invested a total of 597 million yuan, with an investment progress of 99.51%. This change is due to WHO's adjustment of the recommended components of the influenza vaccine. The trivalent influenza vaccine will become the main product promoted in the market, and the production processes of the two types of vaccines are highly co-linked. The changes are still subject to review and approval by the shareholders' meeting.

Kindick announced that the company plans to change the initial fund-raising project in 2021, the “construction project to build a new quadrivalent influenza virus lysis vaccine workshop” to a “construction project to build a new novel trivalent influenza virus lysis vaccine workshop”, and the implementation subject and location remain unchanged. This time, the total investment amount involved was 610 million yuan, accounting for 53.71% of the net capital raised. Of these, the remaining capital raised from the original project was invested an additional 10 million yuan into the new project, mainly for the procurement of raw materials and working materials and supplementary working capital. As of September 30, 2026, the original fund-raising project had invested a total of 597 million yuan, with an investment progress of 99.51%. This change is due to WHO's adjustment of the recommended components of the influenza vaccine. The trivalent influenza vaccine will become the main product promoted in the market, and the production processes of the two types of vaccines are highly co-linked. The changes are still subject to review and approval by the shareholders' meeting.